Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873286 · ClinicalTrials.gov registry record · Phase 2
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT02873286 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 420 participants.
The verdict
NCT02873286, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS). 86 subjects from 2 treatment groups (43 per treatment group) are supposed to receive one (booster) dose of MVA-BN-RSV vaccine approximately one year after their first vaccination. In this booster substudy, eligible subjects will receive the same dose they received during the main trial.
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-RSV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873286
The ClinicalTrials.gov registry entry for NCT02873286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02873286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873286 about?
NCT02873286 is a clinical study titled "RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults". A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS). 86 subjects from 2 treatment groups (43 per treatment group) are supposed to...
What is the current status of trial NCT02873286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2016-09. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02873286?
The interventions under investigation include: Placebo (OTHER), MVA-BN-RSV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02873286?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.